Affiliation:
1. Internal Medicine Department, Port Moresby General Hospital, National Department of Health, Port Moresby, Papua New Guinea
Abstract
The pharmacological treatment of heart failure has evolved over the last three decades since the demonstration of the effect of angiotensin-converting enzyme inhibitors on major cardiovascular events in patients with heart failure with reduced ejection fraction. Composite analysis of heart failure with reduced ejection fraction trials and the recent identification of newer drug treatments show early benefits on the major cardiovascular outcomes, ushering in a change of the treatment strategy; from a ‘sequential’ initiation of the treatments to a ‘simultaneous’ initiation to harness the early benefits. The adoption and implementation of these changes at the bedside have been dismal in many healthcare settings. Papua New Guinea, like many other lower-to-middle-income countries, is facing many barriers that impact on the care of heart failure patients. It needs to adopt and implement these changes to provide evidence-based treatment for its people with heart failure with reduced ejection fraction.
Publisher
Radcliffe Media Media Ltd
Subject
Microbiology (medical),Immunology,Immunology and Allergy
Reference57 articles.
1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104:2855–64. https://doi.org/10.1161/hc4701.099488; PMID: 11733407.
2. McDonagh TA, Metra M, Adamo M, et, al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368; PMID: 34447992.
3. Tromp J, Ferreira JP, Janwanishstaporn S, et al. Heart failure around the world. Eur J Heart Fail 2019;21:1187–96. https://doi.org/10.1002/ejhf.1585; PMID: 31419004.
4. Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail 2022;10:73–84. https://doi.org/10.1016/j.jchf.2021.09.004; PMID: 34895860.
5. Komajda M, Böhm M, Borer JS, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail 2018;20:1315–22. https://doi.org/10.1002/ejhf.1234; PMID: 29806165.